CVRx | Barostim

medical devices

About

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, founded in 2001. The company specializes in Barostim™ therapy, a neuromodulation technology aimed at improving cardiovascular function, particularly for patients with heart failure and resistant hypertension. Its flagship product, the BAROSTIM NEO™, is an implantable device that delivers Baroreflex Activation Therapy (BAT) to help regulate blood pressure and address heart failure progression. The BAROSTIM NEO™ system is customizable for individual patient needs and is the only device with CE Mark approval for both heart failure and resistant hypertension. It is available in over 20 countries and is undergoing clinical evaluation in the United States. CVRx has experienced significant growth, with revenues reaching $38.5 million in 2023 and projected revenues of $56 million to $61 million for 2024. The company aims to enhance global health by leveraging the body's natural systems to improve patient outcomes in cardiovascular care.

Technologies

Salesforce Sendgrid Outlook WP Engine Sophos Remote

Keywords

biotechnology life sciences medical/dental instruments health care medical equipment manufacturing patient-centered treatment medical device clinical trials healthcare equipment and supplies chronic cardiovascular management medical device commercialization baroreflex activation therapy medical devices clinical research medical device safety cardiology resistant hypertension neuromodulation therapy medical device company medical device manufacturing medical device growth global medical device medical device leadership personalized therapy medical device regulation medical device approval heart failure device medical device market hypertension device medical device company culture healthtech

Location

9201 West Broadway Avenue, Minneapolis, Minnesota, United States, 55445

Related Companies

Companies in the same industry